Amuvatinib

Vero E6 cells seeded on a 96-well plate were treated with either amuvatinib (Selleckchem, USA) or imatinib (Axon Medchem, Netherlands). At the indicated time points, cell viability was measured using 30 μL of water-soluble tetrazolium salt (WST; Dail Lab, South Korea) as reported previously (47 (link)).

Afatinib, dasatinib, pazopanib, amuvatinib, crizotinib, sunitinib, sorafenib tosylate and copanlisib were purchased from Selleckchem (Houston, TX). Trypsin-EDTA, DMEM, RPMI, penicillin-streptomycin were purchased from GIBCOBRL (GIBCOBRL Life Technologies, Grand Island, NY). Cells were purchased from the ATCC and were not further validated beyond that claimed by ATCC. Cells were re-purchased every ∼6 months. Commercially available validated short hairpin RNA molecules to knock down RNA / protein levels were from Qiagen (Valencia, CA) or were supplied by collaborators. Reagents and performance of experimental procedures were described in [15 (link)–18 (link)].

2′3′-cGAMP (tlrl-nacga23-02) was purchased from InvivoGen. Ibrutinib (BTK inhibitor; no. S2680), PF-562271 (FAK inhibitor; no. S2890), PP2 (Src inhibitor; no. S7008), saracatinib (Fyn inhibitor; no. S1006), amuvatinib (c-Kit inhibitor; no. S1244), ruxolitinib (Jak1/2 inhibitor; no. S1378), alectinib (ALK inhibitor; no. S2762), gefitinib (EGFR inhibitor; no. S1025), AZD9291 (EGFR inhibitor; no. S7297), and R406 (Syk inhibitor; no. S2194) were obtained from Selleck. Polyethyleneimine (PEI; no. 195444) was purchased from Mpbio, and the transfection procedure was as previously described (16 (link), 33 (link)). Lipofectamine 2000 (no. 11668019) was obtained from Invitrogen. Antibodies against EGFR (no. 4267), GFP (no. 2956), phospho-Syk (Tyr525/526) (no. 2710), Syk (no. 13198), tubulin (no. 2146), and actin (no. 3700) were from Cell Signaling, and hemagglutinin (HA) antibody (ab18181) was purchased from Abcam. STING antibody (A3575) and GST (AE001) antibodies were obtained from Abclonal Technology.